The organization and financing of kidney dialysis and transplant care in the United States of America

被引：36

作者：

Hirth R.A. ^{[1
]}

机构：

[1] Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, MI 48109-2029

来源：

International Journal of Health Care Finance and Economics | 2007年 / 7卷 / 4期

关键词：

Dialysis; End-stage renal disease; Health care financing; Medical costs; Reimbursement; United States;

D O I：

10.1007/s10754-007-9019-6

中图分类号：

学科分类号：

摘要：

In the United States, end-stage renal disease (ESRD) patients are primarily insured by the publicly funded Medicare program. Compared to other countries in the International Study of Health Care Organization and Financing (ISHCOF), the United States has the highest health care expenditures for the general population and among ESRD patients. However, because the Medicare program is more influential in the market for ESRD-related services than for other medical services, ESRD price controls have been relatively stringent. Nonetheless, ESRD costs have grown substantially through increases in prevalence and use of ancillary services. Treatment costs are also controlled by the relatively high rate of transplantation. Proposed reforms include bundling more services into a prospective payment system, developing case-mix adjustments, and financially rewarding providers for quality. © Springer Science+Business Media, LLC 2007.

引用

页码：301 / 318

页数：17

共 26 条

[1]

Bragg-Gresham J.L., Greenwood R., Akizawa T., Kurokawa K., Bailie G.R., Gillespie B.W., Keen M.L., Young E.W., Significant variation exists among the number of medications prescribed for hemodialysis patients across countries: The Dialysis Outcomes and Practice Patterns Study (DOPPS), Journal of the American Society of Nephrology, 14, (2003)

[2]

Program Memorandum Intermediaries/Carriers, (2003)

[3]

2004 Annual Report: ESRD Clinical Performance Measures Project, (2004)

[4]

National Health Expenditure Data, Table 1: National Health Expenditures Aggregate, Per Capita Amounts, Percent Distribution, and Average Annual Percent Growth, By Source of Funds: Selected Calendar Years 1960-2005, (2005)

[5]

Dor A., Pauly M.V., Eichleay M.A., Held P.J., End-stage renal disease and economic incentives: The International Study of Health Care Organization and Financing (ISHCOF), International Journal of Health Financing and Economics, (2007)

[6]

Dykstra D.M., Beronja N., Menges J., Gaylin D.S., Oppenheimer C.C., Shapiro J.R., Wolfe R.A., Rubin R.J., Held P.J., ESRD managed care demonstration: Financial implications, Health Care Financing Review, 24, 4, pp. 59-75, (2003)

[7]

Hirth R.A., Held P.J., Orzol S.M., Dor A., Practice patterns, case mix, Medicare payment policy, and dialysis facility costs, Health Services Research, 33, 6, pp. 1567-1592, (1999)

[8]

Hirth R.A., Chernew M.E., Orzol S.M., Ownership, competition, and adoption of new technologies and cost-saving practices in a fixed price environment, Inquiry, 37, pp. 282-294, (2000)

[9]

Hirth R.A., Roys E.C., Wheeler J.R.C., Messana J.M., Turenne M.N., Saran R., Pozniak A.S., Wolfe R.A., Economic impact of case-mix adjusting the dialysis composite rate, Journal of the American Society of Nephrology, 16, 5, pp. 1172-1176, (2005)

[10]

Leggat J.E., Orzol S.M., Hulbert-Shearon T.E., Golper T.A., Jones C.A., Held P.J., Port F.K., Noncompliance in hemodialysis: Predictors and survival analysis, American Journal of Kidney Diseases, 32, 1, pp. 139-145, (1998)

← 1 2 3 →